AnaptysBio Quarterly Balance Sheets Chart
Quarterly
|
Annual
AnaptysBio Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 44,298,000 | 98,637,000 | 123,080,000 | 191,581,000 | 71,821,000 | 53,695,000 | 35,965,000 | 26,295,000 | 35,206,000 | 94,562,000 | 71,308,000 | 58,547,000 | 71,701,000 | 166,412,000 | 495,729,000 | 336,328,000 | 332,254,000 | 284,148,000 | 250,456,000 | 209,154,000 | 221,172,000 | 165,317,000 | 171,017,000 | 182,898,000 | 146,552,000 | 105,853,000 | 113,596,000 | 293,408,000 | 57,057,000 | 69,474,000 | 81,189,000 | 26,669,000 | 30,752,000 | 96,754,000 | 51,232,000 |
| receivables from collaborative partners | 21,418,000 | 17,884,000 | 40,765,000 | 12,195,000 | 9,007,000 | 7,089,000 | 6,851,000 | 3,269,000 | 3,182,000 | 1,523,000 | 1,419,000 | 1,180,000 | 1,033,000 | 921,000 | 876,000 | 761,000 | |||||||||||||||||||
| short-term investments | 221,412,000 | 241,299,000 | 262,293,000 | 238,536,000 | 278,983,000 | 300,970,000 | 354,939,000 | 386,752,000 | 394,280,000 | 336,589,000 | 369,933,000 | 384,419,000 | 370,450,000 | 339,209,000 | 52,368,000 | 37,736,000 | 58,597,000 | 96,212,000 | 143,197,000 | 129,192,000 | 156,706,000 | 197,166,000 | 203,210,000 | 238,104,000 | 275,664,000 | 309,812,000 | 313,486,000 | 200,406,000 | 210,852,000 | 178,691,000 | 167,218,000 | 89,053,000 | 75,607,000 | 6,742,000 | |
| prepaid expenses and other current assets | 4,778,000 | 5,292,000 | 5,738,000 | 6,369,000 | 7,539,000 | 10,666,000 | 9,080,000 | 11,684,000 | 5,867,000 | 4,480,000 | 4,545,000 | 6,298,000 | 9,625,000 | 5,869,000 | 4,903,000 | 11,759,000 | 6,508,000 | 5,464,000 | 2,908,000 | 7,468,000 | 6,638,000 | 3,572,000 | 3,506,000 | 3,595,000 | 3,772,000 | 6,102,000 | 6,960,000 | 4,035,000 | 3,758,000 | 2,170,000 | 2,688,000 | 3,119,000 | 3,852,000 | 1,694,000 | 1,633,000 |
| total current assets | 291,906,000 | 363,112,000 | 431,876,000 | 448,681,000 | 367,350,000 | 372,420,000 | 406,835,000 | 428,000,000 | 438,535,000 | 437,154,000 | 447,205,000 | 450,444,000 | 452,809,000 | 512,411,000 | 553,876,000 | 386,644,000 | 398,061,000 | 387,131,000 | 396,561,000 | 345,814,000 | 384,516,000 | 371,055,000 | 377,733,000 | 424,597,000 | 430,988,000 | 421,942,000 | 434,216,000 | 503,022,000 | 271,819,000 | 251,945,000 | 252,696,000 | 120,327,000 | 115,848,000 | 110,155,000 | 58,208,000 |
| property and equipment | 1,628,000 | 1,741,000 | 1,849,000 | 1,728,000 | 1,833,000 | 1,954,000 | 2,098,000 | 2,254,000 | 2,023,000 | 1,982,000 | 2,089,000 | 1,972,000 | 2,059,000 | 2,162,000 | 2,283,000 | 2,413,000 | 2,488,000 | 1,754,000 | 1,783,000 | 1,585,000 | 1,495,000 | 1,610,000 | 1,618,000 | 1,695,000 | 1,481,000 | 1,584,000 | 1,445,000 | 1,344,000 | 1,086,000 | 659,000 | 665,000 | 513,000 | 543,000 | 569,000 | 471,000 |
| operating lease right-of-use assets | 13,464,000 | 13,923,000 | 14,383,000 | 14,839,000 | 15,291,000 | 15,732,000 | 16,174,000 | 16,613,000 | 17,047,000 | 17,471,000 | 17,898,000 | 18,320,000 | 18,739,000 | 19,147,000 | 19,558,000 | 19,778,000 | 20,278,000 | ||||||||||||||||||
| long-term investments | 27,996,000 | 43,021,000 | 35,470,000 | 27,914,000 | 42,646,000 | 15,473,000 | 27,026,000 | 40,203,000 | 59,239,000 | 94,929,000 | 142,935,000 | 147,511,000 | 129,985,000 | 91,195,000 | 67,097,000 | 15,242,000 | 5,484,000 | 7,056,000 | 17,546,000 | 36,177,000 | 14,321,000 | 50,215,000 | 54,305,000 | 23,418,000 | 45,707,000 | 68,551,000 | 73,128,000 | 18,616,000 | 32,730,000 | 61,884,000 | 75,897,000 | 999,000 | 13,912,000 | 20,327,000 | |
| other long-term assets | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 256,000 | 258,000 | 258,000 | 477,000 | 602,000 | 1,114,000 | 1,354,000 | 1,293,000 | 1,481,000 | 1,735,000 | 1,913,000 | 2,089,000 | 148,000 | 79,000 | 322,000 | 289,000 | |||||
| total assets | 335,250,000 | 422,053,000 | 483,834,000 | 493,418,000 | 427,376,000 | 405,835,000 | 452,389,000 | 487,326,000 | 517,100,000 | 551,792,000 | 610,383,000 | 618,503,000 | 603,848,000 | 625,171,000 | 643,070,000 | 424,335,000 | 426,569,000 | 396,418,000 | 416,552,000 | 384,750,000 | 401,746,000 | 424,233,000 | 435,197,000 | 451,505,000 | 480,149,000 | 494,226,000 | 508,997,000 | 523,121,000 | 306,017,000 | 314,837,000 | 329,364,000 | 121,945,000 | 130,409,000 | 131,111,000 | 62,180,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||||||||||
| accounts payable | 3,329,000 | 6,123,000 | 4,002,000 | 3,592,000 | 4,890,000 | 4,582,000 | 4,698,000 | 6,521,000 | 4,761,000 | 3,168,000 | 2,784,000 | 3,006,000 | 1,587,000 | 2,481,000 | 1,741,000 | 5,717,000 | 4,103,000 | 2,452,000 | 4,217,000 | 5,484,000 | 6,289,000 | 8,571,000 | 16,237,000 | 10,522,000 | 10,921,000 | 9,072,000 | 5,443,000 | 6,180,000 | 4,426,000 | 2,416,000 | 2,323,000 | 2,557,000 | 3,724,000 | 2,546,000 | 2,278,000 |
| accrued expenses | 30,197,000 | 35,952,000 | 39,501,000 | 38,401,000 | 33,680,000 | 25,903,000 | 30,967,000 | 30,916,000 | 35,164,000 | 30,956,000 | 21,633,000 | 16,453,000 | 16,714,000 | 15,763,000 | 12,853,000 | 14,075,000 | 15,958,000 | 11,826,000 | 15,262,000 | 18,139,000 | 12,916,000 | 13,781,000 | 11,052,000 | 15,286,000 | 14,102,000 | 8,400,000 | 8,761,000 | 7,145,000 | 4,837,000 | 4,405,000 | 4,875,000 | 3,604,000 | 3,230,000 | 4,330,000 | 3,429,000 |
| current portion of operating lease liability | 2,001,000 | 1,962,000 | 1,925,000 | 1,887,000 | 1,850,000 | 1,813,000 | 1,777,000 | 1,741,000 | 1,706,000 | 1,671,000 | 1,637,000 | 1,604,000 | 1,570,000 | 1,537,000 | 1,505,000 | 1,097,000 | 555,000 | ||||||||||||||||||
| total current liabilities | 35,527,000 | 44,037,000 | 45,428,000 | 43,880,000 | 40,420,000 | 32,298,000 | 37,442,000 | 39,178,000 | 41,631,000 | 35,795,000 | 26,054,000 | 21,063,000 | 19,871,000 | 19,781,000 | 16,099,000 | 20,889,000 | 20,616,000 | 14,475,000 | 19,821,000 | 24,474,000 | 20,130,000 | 23,250,000 | 29,535,000 | 29,730,000 | 30,623,000 | 24,754,000 | 21,836,000 | 20,873,000 | 16,790,000 | 14,343,000 | 14,090,000 | 11,174,000 | 10,079,000 | 8,126,000 | 5,708,000 |
| liability related to sale of future royalties | 331,361,000 | 330,382,000 | 353,426,000 | 350,564,000 | 361,981,000 | 310,184,000 | 310,807,000 | 311,272,000 | 310,073,000 | 307,516,000 | 304,413,000 | 301,586,000 | 261,019,000 | 255,584,000 | 251,093,000 | ||||||||||||||||||||
| operating lease liability, net of current portion | 13,095,000 | 13,613,000 | 14,112,000 | 14,607,000 | 15,096,000 | 15,575,000 | 16,037,000 | 16,493,000 | 16,946,000 | 17,388,000 | 17,813,000 | 18,235,000 | 18,652,000 | 19,059,000 | 19,450,000 | 19,838,000 | 20,222,000 | ||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||||||||||||
| common stock | 28,000 | 30,000 | 30,000 | 30,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 29,000 | 28,000 | 28,000 | 28,000 | 28,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 24,000 | 24,000 | 24,000 | 20,000 | 20,000 | 20,000 | 3,000 |
| additional paid in capital | 792,531,000 | 832,486,000 | 829,860,000 | 821,121,000 | 714,959,000 | 706,407,000 | 702,969,000 | 694,591,000 | 686,611,000 | 689,065,000 | 717,797,000 | 707,662,000 | 698,701,000 | 691,161,000 | 678,575,000 | 672,996,000 | 668,429,000 | 664,147,000 | 660,665,000 | 654,492,000 | 651,680,000 | 648,669,000 | 644,148,000 | 640,550,000 | 636,692,000 | 633,251,000 | 629,887,000 | 399,370,000 | 395,424,000 | 393,017,000 | 179,551,000 | 178,297,000 | 176,507,000 | 16,672,000 | |
| accumulated other comprehensive gain | -6,000 | 161,000 | 305,000 | 759,000 | |||||||||||||||||||||||||||||||
| accumulated deficit | -837,286,000 | -798,656,000 | -759,327,000 | -737,543,000 | -704,692,000 | -658,032,000 | -614,096,000 | -571,885,000 | -534,577,000 | -494,732,000 | -450,477,000 | -424,064,000 | -390,562,000 | -358,008,000 | -321,753,000 | -289,215,000 | -282,549,000 | -282,120,000 | -263,957,000 | -297,603,000 | -273,836,000 | -252,288,000 | -244,026,000 | -223,763,000 | -192,730,000 | -168,768,000 | -146,690,000 | -129,696,000 | -113,738,000 | -100,120,000 | -85,034,000 | -78,173,000 | -69,083,000 | -66,399,000 | -54,923,000 |
| total stockholders’ (deficit) equity | -44,733,000 | ||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ equity | 335,250,000 | 422,053,000 | 483,834,000 | 493,418,000 | 427,376,000 | 405,835,000 | 452,389,000 | 487,326,000 | 517,100,000 | 551,792,000 | 610,383,000 | 618,503,000 | 603,848,000 | 625,171,000 | 643,070,000 | 424,335,000 | 426,569,000 | 396,418,000 | 416,552,000 | 384,750,000 | 401,746,000 | 424,233,000 | 451,505,000 | 480,149,000 | 494,226,000 | ||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||||||||||||
| total stockholders’ equity | 34,021,000 | 70,868,000 | 84,367,000 | 9,879,000 | 47,778,000 | 88,103,000 | 120,383,000 | 148,450,000 | 191,093,000 | 262,103,000 | 277,619,000 | 304,306,000 | 330,747,000 | 356,428,000 | 383,608,000 | 385,731,000 | 381,943,000 | 396,731,000 | 360,243,000 | 381,436,000 | 400,564,000 | 405,008,000 | 420,892,000 | 448,421,000 | 468,155,000 | 486,365,000 | 499,677,000 | 284,979,000 | 294,527,000 | 307,581,000 | 101,355,000 | 109,175,000 | 110,115,000 | ||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -415,000 | -624,000 | -797,000 | -2,350,000 | -3,611,000 | -3,267,000 | -5,246,000 | -6,007,000 | -3,861,000 | -2,434,000 | -422,000 | -200,000 | -176,000 | -111,000 | -223,000 | -541,000 | -677,000 | -801,000 | -426,000 | -43,000 | -59,000 | ||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||||||||||||
| long-term restricted cash | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||||||
| short-term restricted cash | 60,000 | ||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||||||
| receivable from collaborative partners | 642,000 | 1,247,000 | 5,000,000 | 5,000,000 | 5,000,000 | 1,225,000 | |||||||||||||||||||||||||||||
| restricted cash | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | ||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||||||
| other current liabilities | 197,000 | 342,000 | 851,000 | 925,000 | 898,000 | 871,000 | 845,000 | 819,000 | 794,000 | 58,000 | 48,000 | 27,000 | 22,000 | 17,000 | 13,000 | 1,000 | |||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||||||||||||
| notes payable, current portion | 1,375,000 | 3,077,000 | 4,781,000 | 6,488,000 | 7,574,000 | 7,500,000 | 7,500,000 | 7,500,000 | 6,875,000 | 5,000,000 | 3,125,000 | 1,250,000 | |||||||||||||||||||||||
| other long-term liabilities | 33,000 | 180,000 | 419,000 | 654,000 | 883,000 | 1,105,000 | 1,317,000 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||||||
| accumulated other comprehensive income | -4,000 | 259,000 | 753,000 | 1,145,000 | 338,000 | 480,000 | 574,000 | 204,000 | -13,000 | ||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||||||
| additional paid-in capital | 657,560,000 | ||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||||||||||||
| australian tax incentive receivable | 175,000 | 174,000 | 173,000 | 152,000 | 1,610,000 | 1,601,000 | 1,486,000 | 5,637,000 | 4,965,000 | 4,118,000 | |||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||||||
| total liabilities, preferred stock and stockholders’ equity | 435,197,000 | 508,997,000 | 523,121,000 | 306,017,000 | 314,837,000 | ||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2019 and december 31, 2018, respectively | |||||||||||||||||||||||||||||||||||
| liabilities, preferred stock andstockholders’ equity | |||||||||||||||||||||||||||||||||||
| notes payable, net of current portion | 625,000 | 2,409,000 | 4,120,000 | 5,834,000 | 7,553,000 | 9,269,000 | 10,987,000 | 12,709,000 | 13,809,000 | ||||||||||||||||||||||||||
| deferred rent | 171,000 | 162,000 | 128,000 | 133,000 | 140,000 | 147,000 | 168,000 | 161,000 | 154,000 | ||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at december 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||
| liabilities, preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at september 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at june 30, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at march 31, 2018 and december 31, 2017, respectively | |||||||||||||||||||||||||||||||||||
| long-term vendor deposits | 46,000 | 46,000 | 46,000 | ||||||||||||||||||||||||||||||||
| deferred financing costs | 3,441,000 | ||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock andstockholders’ equity | |||||||||||||||||||||||||||||||||||
| preferred stock warrant liabilities | 3,241,000 | ||||||||||||||||||||||||||||||||||
| commitments and contingencies | |||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, no shares and 3,963 authorized, issued and outstanding at december 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, no shares and 1,887 shares authorized, no shares and 1,593 shares issued and outstanding at december 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c-1 convertible preferred stock, 0.001 par value, no shares and 474 shares authorized, issued and outstanding at december 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.001 par value, no shares and 5,491 shares authorized, issued and outstanding at december 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares and no shares authorized, issued or outstanding at december 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 329,364,000 | 121,945,000 | 130,409,000 | 131,111,000 | |||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, no shares and 3,963 authorized, issued and outstanding at september 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, no shares and 1,887 shares authorized, no shares and 1,593 shares issued and outstanding at september 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c-1 convertible preferred stock, 0.001 par value, no shares and 474 shares authorized, issued and outstanding at september 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.001 par value, no shares and 5,491 shares authorized, issued and outstanding at september 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares and no shares authorized, issued or outstanding at september 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, no shares and 3,963 authorized, issued and outstanding at june 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, no shares and 1,887 shares authorized, no shares and 1,593 shares issued and outstanding at june 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c-1 convertible preferred stock, 0.001 par value, no shares and 474 shares authorized, issued and outstanding at june 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.001 par value, no shares and 5,491 shares authorized, issued and outstanding at june 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares and no shares authorized, issued or outstanding at june 30, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, no shares and 3,963 authorized, issued and outstanding at march 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, no shares and 1,887 shares authorized, no shares and 1,593 shares issued and outstanding at march 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series c-1 convertible preferred stock, 0.001 par value, no shares and 474 shares authorized, issued and outstanding at march 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.001 par value, no shares and 5,491 shares authorized, issued and outstanding at march 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000 shares and no shares authorized, issued or outstanding at march 31, 2017 and december 31, 2016, respectively | |||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||||||||||||
| deferred revenue | |||||||||||||||||||||||||||||||||||
| income taxes payable | |||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, 3,963 shares authorized, issued and outstanding at december 31, 2016 and 2015; aggregate liquidation preference at december 31, 2016 of 24,991 | 28,220,000 | ||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, 1,887 shares authorized, 1,593 shares issued and outstanding at december 31, 2016 and 2015; aggregate liquidation preference at december 31, 2016 of 7,246 | 6,452,000 | ||||||||||||||||||||||||||||||||||
| series c-1 convertible preferred stock, 0.001 par value, 474 shares authorized, issued and outstanding at december 31, 2016 and 2015, respectively; aggregate liquidation preference at december 31, 2016 of 6,470 | 2,156,000 | ||||||||||||||||||||||||||||||||||
| series d convertible preferred stock, 0.001 par value, 5,491 shares authorized, issued and outstanding at december 31, 2016 and 2015, respectively; aggregate liquidation preference at december 31, 2016 of 40,767 | 40,688,000 | ||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | |||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -38,248,000 | ||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 62,180,000 | ||||||||||||||||||||||||||||||||||
| collaboration revenue | 16,684,000 | ||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||
| research and development | 15,419,000 | ||||||||||||||||||||||||||||||||||
| general and administrative | 4,290,000 | ||||||||||||||||||||||||||||||||||
| total operating expenses | 19,709,000 | ||||||||||||||||||||||||||||||||||
| income from operations | -3,025,000 | ||||||||||||||||||||||||||||||||||
| other income | -20,000 | ||||||||||||||||||||||||||||||||||
| interest expense | -458,000 | ||||||||||||||||||||||||||||||||||
| interest expense, related parties | |||||||||||||||||||||||||||||||||||
| change in fair value of liability for preferred stock warrants | -756,000 | ||||||||||||||||||||||||||||||||||
| total other income | -1,234,000 | ||||||||||||||||||||||||||||||||||
| income before income taxes | -4,259,000 | ||||||||||||||||||||||||||||||||||
| benefit from income taxes | |||||||||||||||||||||||||||||||||||
| net income | -4,259,000 | ||||||||||||||||||||||||||||||||||
| net income attributed to participating securities | |||||||||||||||||||||||||||||||||||
| net income attributed to common stockholders | -4,259,000 | ||||||||||||||||||||||||||||||||||
| net income per common share: | |||||||||||||||||||||||||||||||||||
| basic and diluted | -1,620 | ||||||||||||||||||||||||||||||||||
| weighted-average number of shares outstanding: |
We provide you with 20 years of balance sheets for AnaptysBio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AnaptysBio. Explore the full financial landscape of AnaptysBio stock with our expertly curated balance sheets.
The information provided in this report about AnaptysBio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.